|
業務類別
|
Biotechnology |
|
業務概覽
|
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications. |
| 公司地址
| 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063 |
| 電話號碼
| +1 847 673-1700 |
| 傳真號碼
| +1 847 556-6411 |
| 公司網頁
| https://www.exicuretx.com |
| 員工數量
| 8 |
| Mr. Joshua Miller |
Chief Accounting Officer |
-- |
25/03/2026 |
| Mr. Young Seung Ko |
Chief Operating Officer |
-- |
10/04/2026 |
| Mr. Gyuyeob Lee |
Interim Chief Financial Officer and Secretary |
-- |
17/02/2026 |
| Mr. Jung Soo Kim |
Director, President and Chief Executive Officer |
-- |
17/02/2026 |
|
|
| Mr. Jung Kyu Ham |
Director |
10/02/2026 |
| Mr. Seog Cheon Gyeung |
Director |
10/02/2026 |
| Mr. Yoontae Han |
Director |
10/04/2026 |
| Mr. Gyeong Seog Cheon |
Independent Director |
25/03/2026 |
| Mr. Jung Soo Kim |
Director, President and Chief Executive Officer |
17/02/2026 |
| Mr. Dongho Lee |
Independent Director |
25/03/2026 |
|
|
|
|
